A new trading day began on Friday, with Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) stock price down -0.15% from the previous day of trading, before settling in for the closing price of $0.80. LXRX’s price has ranged from $0.73 to $3.73 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 186.21% over the last five years. Meanwhile, its annual earnings per share averaged 14.05%. With a float of $168.63 million, this company’s outstanding shares have now reached $244.92 million.
The firm has a total of 285 workers. Let’s measure their productivity. In terms of profitability, gross margin is 87.97%, operating margin of -4037.43%, and the pretax margin is -4109.41%.
Lexicon Pharmaceuticals Inc (LXRX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lexicon Pharmaceuticals Inc is 53.35%, while institutional ownership is 29.62%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000.
Lexicon Pharmaceuticals Inc (LXRX) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.2 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.05% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Here are Lexicon Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Analysing the last 5-days average volume posted by the [Lexicon Pharmaceuticals Inc, LXRX], we can find that recorded value of 4.3 million was better than the volume posted last year of 3.49 million. As of the previous 9 days, the stock’s Stochastic %D was 23.37%. Additionally, its Average True Range was 0.11.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 4.28%, which indicates a significant decrease from 12.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.26% in the past 14 days, which was lower than the 109.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4578, while its 200-day Moving Average is $1.8228. Now, the first resistance to watch is $0.8218. This is followed by the second major resistance level at $0.8398. The third major resistance level sits at $0.8597. If the price goes on to break the first support level at $0.7839, it is likely to go to the next support level at $0.7640. Now, if the price goes above the second support level, the third support stands at $0.7460.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
With a market capitalization of 290.10 million, the company has a total of 246,237K Shares Outstanding. Currently, annual sales are 1,200 K while annual income is -177,120 K. The company’s previous quarter sales were 1,750 K while its latest quarter income was -64,810 K.
